Tag: Tnf inhibitors

In clinical trials, approximately 37% of patients treated with Enbrel for rheumatologic indications developed mild to moderate injection site reactions. Understanding the full spectrum of patient experiences, including both common side effects and the therapeutic benefits, is key to managing expectations when asking, "How do you feel after taking Enbrel?"

Approximately 8% of the U.S. population lives with an autoimmune disease, many of whom are treated with biologic drugs [1.11.1, 1.11.2]. When considering treatment, it's vital to ask: **What is the difference between Remicade and Humira?** These are two common, yet distinct, options.

With over 1.5 million Americans diagnosed with rheumatoid arthritis (RA), finding an effective treatment is critical. The question of what's the best biologic for rheumatoid arthritis is complex, with the ideal choice varying significantly based on individual patient factors and disease characteristics.

According to a 2020 report, Enbrel (etanercept) was administered to approximately one million people in the US alone for various autoimmune conditions. When considering **what drug is comparable to Enbrel**, patients have several options, from similar TNF blockers to different classes of targeted therapies, each with unique mechanisms and considerations.

In Japan, over 18,000 patients have received treatment for Behçet's disease, a form of vasculitis, for which Humira is an approved therapy [1.10.1]. The question remains, **does Humira work for vasculitis** in its other forms? This article explores its use.

Drug-induced vasculitis accounts for approximately 3% of all vasculitis cases [1.2.1]. This condition involves inflammation of blood vessels triggered by certain medications. Understanding **which drugs cause vasculitis** is the first step toward diagnosis and management.